

1 **Full title: Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and**
2 **SARS-CoV-2 variants**

3 **Running title: Broad Neutralization Antibodies against SARS-CoV-2 Variants**

4

5 Yuanyuan QU^{1*}, Xueyan Zhang^{2,7*}, Meiyu WANG^{3,8*}, Lina SUN^{1*}, Yongzhong JIANG⁴,
6 Cheng Li⁵, Wei WU¹, Zhen Chen², Qiangling YIN¹, Xiaolin JIANG⁶, Yang LIU¹, Chuan LI¹,
7 Jiandong LI¹, Tianlei Ying⁵, Dexin LI¹, Faxian ZHAN⁴, Youchun WANG^{3,8}, Wuxiang
8 GUAN^{2#}, Shiwen WANG^{1#}, Mifang LIANG^{1#}

9

10 1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute
11 for Viral Disease Control and Prevention, China CDC, Beijing 102206, China;

12 2. Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy
13 of Sciences, Wuhan, Hubei 430071, China;

14 3. Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological
15 Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629,
16 China;

17 4. Hubei Provincial Center for Disease Control and Prevention, Wuhan 430065, China;

18 5. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic
19 Medical Sciences, Fudan University, Shanghai 200032, China;

20 6. Shandong Center for Disease Control and Prevention, Jinan 250014, China;

21 7. University of Chinese Academy of Sciences, Beijing, 100049, China;

22 8. Peking Union Medical College, Beijing 100730, China.

23 * Yuanyuan QU, Xueyan Zhang, Meiyu WANG, Lina SUN contributed equally to the article.

24

25 # Correspondence Authors:

26 Correspondence to:

27 Prof.Dr.Shiwen WANG E-mail: wangsw@ivdc.chinacdc.cn

28 Prof.Dr. Wuxiang GUAN E-mail: guanwx@wh.iov.cn

29 Prof.Dr.Mifang LIANG E-mail: liangmf@ivdc.chinacdc.cn

30

31 **Abstract**

32 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated
33 multiple variants resistant to therapeutic antibodies. In this study, 12 high-affinity antibodies
34 were generated from convalescent donors in early outbreaks using immune antibody phage
35 display libraries. Of them, two RBD-binding antibodies (F61 and H121) showed high affinity
36 neutralization against SARS-CoV-2, whereas three S2-target antibodies failed to neutralize
37 SARS-CoV-2. Following structure analysis, F61 identified a linear epitope located in residues
38 G446 - S494, which overlapped with angiotensin-converting enzyme 2 (ACE2) binding sites,
39 while H121 recognized a conformational epitope located on the side face of RBD, outside
40 from ACE2 binding domain. Hence the cocktail of the two antibodies achieved better
41 performance of neutralization to SARS-CoV-2. Importantly, F61 and H121 exhibited efficient
42 neutralizing activity against variants B.1.1.7 and B.1.351, those showed immune escape.
43 Efficient neutralization of F61 and H121 against multiple mutations within RBD revealed a
44 broad neutralizing activity against SARS-CoV-2 variants, which mitigated the risk of viral
45 escape. Our findings defined the basis of therapeutic cocktails of F61 and H121 with broad
46 neutralization and delivered a guideline for the current and future vaccine design, therapeutic
47 antibody development, and antigen diagnosis of SARS-CoV-2 and its novel variants.

48 **Keywords:** Antibody Cocktail, Severe acute respiratory syndrome coronavirus 2
49 (SARS-CoV-2), Broad neutralization, SARS-CoV-2 variants, Angiotensin-converting enzyme
50 2 (ACE2),

51

52 **Introduction**

53 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is acknowledged as the
54 novel coronavirus that causes the global pandemic of COVID-19 (Andersen *et al.*, 2020). Up
55 to 28 February 2021, over 100 million confirmed cases have been reported worldwide (World
56 Health Organization). SARS-CoV-2 grouped to the betacoronavirus genus (Wu *et al.*, 2020)
57 is proved to share about 80% sequence identity to SARS-CoV and target the same cellular
58 receptor, angiotensin-converting enzyme 2 (ACE2) (Daniel *et al.*, 2020). ACE2 directly binds
59 to SARS-CoV-2 spike (S) protein which is consisted of S1 subunit and S2 subunit (Daniel
60 *et al.*, 2020).

61 To date, a variety of neutralizing antibodies against SARS-CoV-2 S protein have been
62 generated. Potent neutralizing often found to target S1 subunit (Hwang *et al.*, 2006), which
63 consists of the N-terminal domain (NTD) and the receptor-binding domain (RBD). However,
64 neutralizing antibodies targeting the S2 subunit still need to be discovered (Liu *et al.*, 2020;
65 Wec *et al.*, 2020). The NTD-specific monoclonal antibodies (mAbs) target a patch remote
66 from RBD (Chi *et al.*, 2020; Liu *et al.*, 2020). RBD-specific mAbs are divided into four main
67 classes (Barnes *et al.*, 2020b). Antibodies grouped in class one and class two, such as CB6
68 (Shi *et al.*, 2020) and P2B-2F6 (Ge *et al.*, 2021), are found with high potencies and
69 overlapped with the receptor-binding motif (RBM) on RBD (Ju *et al.*, 2020; Shi *et al.*, 2020;
70 Wu *et al.*, 2020). These mAbs are dominant in convalescent serum (Piccoli *et al.*, 2020).
71 Antibodies in the third and fourth class, like S309 (Pinto *et al.*, 2020) and CR3022 (Piccoli *et*
72 *al.*, 2020; Xiang *et al.*, 2020), are positioned detached from the RBM (Starr *et al.*, 2020)..

73 The rapid global spread and transmission of SARS-CoV-2 are hypothesized to provide
74 the virus with substantial opportunities for the natural selection of favorable mutations, many

75 of which involved modification of S protein. The D614G mutation in the S protein enhances
76 viral transmission and overtakes the prime strain of SARS-CoV-2 (Zhang *et al.*, 2020; Li *et*
77 *al.*, 2021). The recent emerging variants of concern observed in the United Kingdom(B.1.1.7
78 with mutations N501Y, A570D and del69/70), South Africa (B.1.351 with mutations K417N,
79 E484K and N501Y), and Brazil (P.1 and P.2 with mutations K417T, E484K and N501Y)
80 (Long *et al.*, 2021) initially respond more tightly to ACE2 and appear to be more infectious to
81 human (Laffeber *et al.*, 2021; Tian *et al.*, 2021). More severely, B.1.351 and P.1 are resistant
82 to convalescent plasma, vaccine sera and multiple neutralizing mAbs (Hoffmann *et al.*, 2021;
83 Widera *et al.*, 2021). Variants B.1.141 and B.1.258 with mutation N439K increase spike
84 affinity for ACE2 and confer resistance to several mAbs (Thomson *et al.*, 2021). American
85 variants(B.1.429 and B.1.427)containing L452R(Long *et al.*, 2021) show refractory to mAbs
86 as well. SARS-CoV-2 variants isolated from minks and mouse harboring mutations G261D,
87 A262S, L452M, Y453F, F486L, Q498H and N501T may cause potential cross-species
88 transmission that worth closely monitor (Thomson *et al.*, 2021; Yao *et al.*, 2021). Thus, it is
89 essential to develop antibodies with broad-spectrum activities against SARS-CoV-2 and
90 SARS-CoV-2 variants.

91 A variety of neutralizing antibodies against SARS-CoV-2 have entered clinical trials.
92 However, the virus may persist due to mutations, especially mutations on the S protein,
93 leading to dropping neutralizing activity and hence efficacy from these neutralizing antibodies
94 in the longer term (Li *et al.*, 2020). Therefore, it is essential to develop various neutralizing
95 antibodies against different epitopes. Besides, novel delivery strategies of antibodies, such as
96 antibody inhalation treatment, would be encouraged and benefit from the convenience and

97 widely applied during COVID-19 prevention.

98 Here we reported 12 mAbs screened with purified SARS-CoV-2 RBD, S1 and S2 from
99 three COVID-19 convalescent patients by phage antibody library technique. Then we
100 characterized their affinity, neutralizing activity and binding sites. We also evaluated
101 the neutralizing activity of screened mAbs to SARS-CoV-2 variant. Additionally we selected
102 two RBD-specific antibodies (F61 and H121) with high neutralizing activity and high affinity
103 to investigate interaction between antibodies and RBD via computer simulation. Our research
104 provided a theoretical basis for the development of therapeutic antibodies.

105

106 **Materials and Methods**

107 **Cells and Viruses**

108 Cell lines (HEK293T and VeroE6 cells) were initially acquired from the American Type
109 Culture Collection (ATCC; USA). EXPi293F cells were purchased from Life Technologies,
110 USA. They were cultured at 37 °C under 5% CO₂ in Dulbecco's modified Eagle's medium
111 (DMEM; Life Technologies, USA) supplemented with 10% heat-inactivated fetal bovine
112 serum (FBS; Life Technologies, USA) and 1% penicillin/streptomycin (Life Technologies,
113 USA) or in EXPI293 expression medium (Life Technologies, USA). Cells were passaged
114 every two days and digested with 0.05% trypsin-EDTA. Pseudovirus of SARS-CoV-2
115 (GenBank: MN908947) and SARS-CoV-2 variants were obtained from National Institutes for
116 Food and Drug Control. The authentic SARS-CoV-2 (GenBank: MN908947) and
117 SARS-CoV-2 variants were obtained from Wuhan Institute of Virology. All work with

118 infectious SARS-CoV-2 was performed in Institutional Biosafety Committee approved BSL3
119 facilities using appropriate positive pressure air respirators and protective equipment.

120

121 **Construction and Screening of Human Antibody Phage Display Library.**

122 The phage display library procedures in the vector pComb 3H followed the methods
123 described previously (Kashyap *et al.*, 2008). Briefly, lymphocytes were isolated from three
124 convalescent donors in early outbreaks which were selected by Enzyme-Linked
125 Immunosorbent (ELISA) assays and colloidal gold test (INNOVITA, CHN). Total cellular
126 mRNA was extracted using the RNeasy Mini kit (Qiagen, GER), and cDNA was synthesized
127 with primer oligo (dT) using Transcriptor High Fidelity cDNA Synthesis kit (Roche, SUI).
128 PCR amplification was then performed using FastStrat High Fidelity PCR System (Roche,
129 SUI). The light and heavy chain genes were amplified from the cDNA by PCR using the
130 primer pairs from VK, VL and VH gene families, then cloned into the vector pComb
131 3H(Barbas *et al.*, 1991). The library's initial diversity was evaluated and assured by
132 sequencing of randomly picked clones for each step of library construction and the
133 complexity of the library was then calculated. The final yielded antibody libraries were
134 panned and screened with purified SARS-CoV-2 RBD protein, S1 protein and S2 protein
135 (Jiangsu East-Mab Biomedical Technology, CHN) following the standard panning
136 procedure(Barbas and Burton, 1996).

137

138 **Production of monoclonal antibody.**

139 For recombinant human mAb production, the cDNA encoding mAb variable regions of
140 the heavy and light chains were cloned into expression plasmids containing the human IgG1
141 heavy chain and Ig kappa or lambda light chain constant regions, respectively. Recombinant
142 mAbs were then produced in EXPi293F cells (Life Technologies, USA) by transfecting pairs
143 of the IgG1 heavy and light chain expression plasmids. Human antibodies purified by
144 Protein-G (GE Healthcare, USA) affinity chromatography were stored at -80°C until use.

145

146 **Enzyme-Linked Immunosorbent (ELISA) Assays and non-competitive ELISA assay**

147 ELISA plates were coated with SARS-CoV-2 RBD protein, S1 protein, S2 protein, S
148 protein trimer and mutant S1 protein (Jiang-su East-Mab Biomedical Technology, CHN) at 4
149 °C overnight. Following washing with PBST, serial dilutions of testing antibodies start at
150 1µg/ml or serial dilutions of plasma start at 1:100 were added to each well and incubated at 37
151 ° C for 30min. After washing with PBST, horseradish peroxidase (HRP)-conjugated
152 anti-human IgG antibody (Sigma, USA) was added at the dilution of 1:20000 and incubated
153 at 37° C for 30min. The absorbance was detected at 450nm. The data was analyzed using
154 GraphPad Prism 8.0.

155

156 **Surface plasmon resonance (SPR) assay**

157 Purified antibodies targeting S1 were quantified with SPR assay using the BIAcore
158 8000 system (GE Healthcare, USA) carried out at 25°C in single-cycle mode. Purified
159 SARS-CoV-2 S1 diluted in 10 mM sodium acetate buffer (PH 5.5) was immobilized to CM5
160 sensor chip by amine coupling reaction. Serially diluted antibodies were injected with a rate

161 of 30 ml/min in sequence. The equilibrium dissociation constants (binding affinity, K_d) for
162 each antibody were calculated using Biacore 8000 Evaluation Software.

163

164 **Virus neutralization assay.**

165 The virus neutralization assay with pseudoviruses was conducted as described previously
166 (Nie *et al.*, 2020). Briefly, serially diluted antibodies were added into 96-well plates. After
167 that, 50 µl pseudoviruses were added to the plates, followed by incubation at 37°C for one
168 hour. Afterward, HuH-7 cells were added into the plates (2×10^4 cells/100 µl per well),
169 followed by 24h incubation at 37°C in a humidified atmosphere with 5% CO₂.
170 Chemiluminescence detection was performed straight after, and the Reed-Muench method
171 was used to calculate the virus neutralization titer. The half-maximal inhibitory
172 concentrations (IC₅₀) were determined using 4-parameter logistic regression (GraphPad
173 Prism version 8).

174 Authentic SARS-CoV-2 was used in the plaque reduction neutralization test (PRNT). In
175 brief, the mAbs were trifold serially diluted in culture medium and mixed with SARS-CoV-2
176 (200 PFU) for one hour. Mixtures were then transferred to 24-well plates seeded with Vero
177 E6 cells and allowed absorption for 1 h at 37 °C. Inoculums were then removed before adding
178 the overlay media (100 µl MEM containing 1 % carboxymethylcellulose, CMC). The plates
179 were then incubated at 37 °C for 96 h. Cells were fixed with 4% paraformaldehyde solution
180 for one day, and overlays were removed. Cells were incubated with 1% crystal violet for five
181 minutes at room temperature. The half-maximal inhibitory concentrations (IC₅₀) were
182 determined using 4-parameter logistic regression (GraphPad Prism version 8).

183

184 **Fluorescence-activated cell sorting (FACS) assay**

185 SARS-CoV-2 S protein-expressing plasmids were transfected into HEK293T cells using
186 Lipofectamine 3000 (Invitrogen, USA). 24 h after transfection, cells were suspended and
187 washed with PBS twice. Then the cells were incubated with 20 µg/ml mAbs or isotype IgG
188 mAb of hepatitis b virus (HBV), at room temperature for 1 h, followed by further incubation
189 with anti-human IgG FITC-conjugated antibody (Sigma, USA). The cells were analyzed
190 using FACS Aria II (BD, USA). All of these data were analyzed using FlowJo.

191 The block assay was assessed by FACS. HEK293T cells were transiently transfected
192 with the ACE2 expression plasmid for 24 h. The mouse-Fc tag Fusion protein of
193 SARS-CoV-2 RBD (RBD-mFc) (Jiang-su East-Mab Biomedical Technology, CHN) at a
194 concentration of 2 µg/ml was mixed with the mAbs or isotype IgG at a molar ratio of 1:10
195 and incubated at 4 °C for 1 h. Then mixtures were added to 2.5×10^5 HEK293T cells
196 expressing ACE2 and incubated at 4 °C for another hour. Then cells were stained with
197 anti-mouse IgG Texas red-conjugated antibody and anti-human IgG FITC-conjugated
198 antibody (Sigma, USA) for another 30 min then analyzed by FACS Aria II (BD, USA).

199

200 **Competition ELISA assay.**

201 Plates were coated with SARS-CoV-2 RBD (Jiang-su East-Mab Biomedical Technology,
202 CHN) at 4 °C overnight. Two-fold serial dilutions antibodies were added to the wells, and
203 plates were incubated for one hour at 37°C. Then plates were incubated with HRP-conjugated
204 mAb (diluted 1:2000) (Wantai BioPharm, CHN) for 30min at 37°C. HRP activity was

205 measured at 450 nm. Paired antibodies with a value less than 20% were defined as
206 noncompeting. Antibodies were deemed to compete for the same epitopes if the value was
207 calculated greater than 60%. Otherwise, if the value was found between 20% and 60%, the
208 antibody pairs were considered partially overlapping. The percent of binding inhibition of
209 labeled antibodies was calculated according to the formula below:

210

$$f = \frac{A_{450}(\text{uninhibited}) - A_{450}(\text{inhibited})}{A_{450}(\text{uninhibited})} \times 100\%$$

211

212

213 **Molecular Modeling and Docking of the antibodies to RBD**

214 The computational simulation was carried out by Discovery studio 2.0 (Accelrys, San
215 Diego, CA)(Kaushik and Sowdhamini, 2011). A suitable template was obtained through a
216 BLAST search of the Protein Databank (PDB). The homology modeling of mAbs was
217 performed using DS Homology Modeling protocol, and the 3D model of antibody was
218 optimized using Antibody loop refinement protocol. The models were validated by
219 Ramachandran plots. Protein-protein docking of RBD and mAbs was performed using the
220 ZDOCK and RDOCK programs by specifying the variable region's antibody residues on the
221 binding interface. RDOCK refinement was performed on the top 100 poses of the filtered
222 ZDOCK output and applied scoring function to each docked structure for best binding
223 models.

224

225 **Result**

226 **Generation and screening of Antibodies Against SARS-CoV-2.**

227 To isolate mAbs, we collected plasma and peripheral blood mononuclear cells (PBMCs)
228 from 15 confirmed COVID-19 convalescent patients in Hubei and Shandong Province. We
229 evaluated antibodies titer in plasma to SARS-CoV-2 N protein and different fragments of S
230 protein, including RBD, S1, and S2 with ELISA (Fig. 1A) and colloidal gold test (data not
231 shown). The plasma from donors 2, 10 and 11 showed higher IgG titer against RBD, S1 and
232 S2. Thus they were chosen for library construction by the pComb 3H vector system. The
233 library was established with a complexity of 1×10^8 estimated independent clones and 100%
234 Fab genes diversity after sequencing confirmation. Single clone screening was performed
235 with ELISA, and a total of 274 positive monoclonal were identified (Fig. 1B). Based on
236 sequencing and ELISA results, four unique clones from RBD, five from S1, and three from
237 S2 were chosen as the candidates for further interrogation.

238 In order to analysis the characteristics of selected Fab antibodies, we recloned the Fab
239 antibodies into the IgG1 format. We further determined the binding specificity of the 12
240 candidate IgGs with purified SARS-CoV-2 virion and different S protein fragments (S1, S2,
241 RBD and S protein trimer) utilizing ELISA. All 12 antibodies were able to recognize purified
242 SARS-CoV-2 virion and S protein trimer. However, the binding strength of 12 antibodies to
243 purified SARS-CoV-2 virion varied. A199, B15, H278, B120 and H285 had a weak affinity
244 to virion. Nine antibodies (F61, F163, B15, H121, C25, A8, H184, B110 and A199) screened
245 with purified RBD and S1 were all positive to RBD. The rest three of them (H278, B120 and
246 H285) were found attached to S2 but not S1 nor RBD (Fig. 1C). However, NTD specific
247 mAbs were not screened and identified.

248

249 **Characterizing the binding profile of 12 candidate antibodies**

250 The specificity of candidate SARS-CoV-2 specific IgGs were evaluated utilizing FACS.
251 All candidate IgGs (labeled by FITC) showed positive on the surface of HEK293 T cells
252 expressing SARS-CoV-2 S protein. In contrast, HBV mAb, as a negative control,
253 demonstrated no interaction with S protein (Fig. 2A and Fig.S1 A). Thus, all tested mAbs
254 were suggested binding specifically to SARS-CoV-2 S protein.

255 SPR assay were performed to evaluate the affinity of nine RBD-specific IgGs to S1
256 protein. F61, F163, H121, C25, H184, B110 and A199 showed a high affinity to S1 protein.
257 The KD values ranged from $1.45 \times 10^{-12} \text{M}$ to $4.88 \times 10^{-12} \text{M}$. In comparison, lower KD values
258 were detected regarding B15 and A8 (Fig. 2B and Fig.S1 B). Non-competitive ELISA assay
259 were performed to evaluate the affinity of H278, B120 and H285 against S2 protein. The KD
260 values of H278, B120 and H285 were $2.15 \times 10^{-11} \text{M}$, $2.6 \times 10^{-11} \text{M}$, $2.74 \times 10^{-11} \text{M}$,
261 respectively(data not show)

262 Neutralizing capacity of 12 candidate IgGs were evaluated by authentic SARS-CoV-2
263 neutralization assay and pseudoviruses neutralization assay. F61, H121 and F163 exhibited
264 high neutralizing capacity with IC₅₀ of 0.46 ug/ml, 0.48 ug/ml, and 0.64 ug/ml to authentic
265 SARS-CoV-2, and 0.027 ug/ml, 0.078 ug/ml, and 0.095 ug/ml to pseudoviruses, respectively.
266 However, A199 exhibited low neutralizing capacity, which which suggested not all
267 RBD-specific antibodies were neutralizing antibodies. S2-specific mAbs failed to neutralize
268 SARS-CoV-2 (data not shown). Moreover, the cocktail of F61 and H121 exhibited a
269 synergistic neutralization to authentic SARS-CoV-2 with the neutralizing capacity (0.13
270 ug/ml) increased four times compared to each one alone (Fig. 2C).

271 To further characterize nine RBD-specific IgGs, we then analyzed antigenic epitopes of
272 nine RBD-specific antibodies by competitive ELISA. Antibodies were roughly classified into
273 three groups by competition percentages. Group one contained F61, F163 and B15. Group
274 two included H121, C25, A8, H184 and B110. Group one and group two were not
275 competitive, which suggested they bound to different antigenic epitopes. A199 from group
276 three had no competition with mAbs in group one yet a partial competition with those from
277 group two. A199 bound to a non-neutralization epitope on RBD (Fig. 3A).

278 The inhibitory effect of these antibodies on the RBD-ACE2 interaction was investigated
279 by FACS using ACE2 expressing HEK293T cells. F61 and F163 from group one prevented
280 RBD from binding to ACE2 with no fluorescence signal from the antibody (FITC) or RBD
281 (Taxes red), which suggested they bound to an ACE2-competitive epitopes. B15 only partly
282 blocked the binding of RBD to ACE2 due to its low affinity and neutralization capacity. In
283 group two, H121, C25, A8, H184 and B110 failed to block the binding between RBD and
284 ACE2 with double-positive cells to antibody and RBD. Their epitopes were far from
285 ACE2-binding domain on RBD. As the neutralization capacity of antibodies decreased, more
286 cells showed double-positive to antibody and RBD. The proportion of double-positive cells to
287 H121, which suggested the highest neutralization capacity and affinity, was 17%. The
288 proportion of double-positive cells to H184, one with lower neutralization capacity, was
289 19.7%. A199 was also double-positive to antibody and RBD. The neutralizing capacity of
290 A199 was negligible, consistent with its poor performance in preventing the binding of ACE2
291 to RBD with the highest proportion of double-positive cells (Fig. 3B).

292 So far, we have obtained three types of antibodies, one of which is mainly represented by
293 F61 and F163 to recognize ACE2 receptor epitopes with high neutralization activity. One is
294 represented by H121 to identify epitopes which not overlap with ACE2 binding sites, but it
295 has high neutralization activity. And the last one is A199 which bound to a non-overlapping
296 epitope with ACE2 binding sites had no neutralization activity.

297 **Interaction between mAbs and RBD via Computer Modeling and Docking.**

298 F61 and H121 exhibited the high neutralization capacity and bound to different epitopes.
299 They were excellent candidate of antibody-based drugs to SARS-CoV-2. To precisely
300 delineate the interaction between antibody and antigen. We further investigated interaction
301 between F61/ H121 and RBD via computer simulation. Crystal structures that shared over
302 90% sequence similarity with F61 and H121 were used as the antibody template to build the
303 3D-structure of the two antibodies. Meanwhile, crystal structure 7DK3 (PDB) (Daniel *et al.*,
304 2020) of SARS-CoV-2 RBD was used in the ZDOCK program and RDOCK program.

305 The outcomes demonstrated that F61 and H121 bind to diversified regions on RBD. F61
306 identified a linear epitope ranging from G446 to S494 within the RBM region involving 23
307 residues on RBD (Fig. 4A). The predicted binding sites indicated both the light and the heavy
308 chain of F61. In specific, hydrogen-bond (H-bond) could be formed upon approaching RBD's
309 P479, C480, N481 and F486 with D108, N37 and S109 on the F61's light chain, as well as
310 F490 and L492 with G109 and R36, E484 with Y38 and Y114 on the heavy chain (Fig.4B,
311 upper panel). In comparison, H121 recognized a conformational epitope located remote from
312 the RBM region and mainly contributed by the heavy chain (Fig. 4A). Specifically, R355,

313 G381 and L517 on RBD formed H-bond with S11A, N59 and Y109, L518 and A520 to Y37
314 on the heavy chain. R357 bond to Y38 on the light chain (Fig.4B, lower panel).

315 The antibody-RBD complex structure was subsequently aligned with the ACE2-RBD
316 complex based on the RBD sequence (Fig.4C upper panel). Six residues within the F61
317 epitopes overlapped the ACE2-binding sites on the RBD. H121 positioned further away from
318 the ACE2-binding sites and hence showed no competitiveness in previous assays (Fig.4C
319 lower panel).

320 **Determination of the effects of natural mutations in S protein on the sensitivity of**
321 **candidate antibodies.**

322 All S protein mutations (reported in the GISAID database up to 19 January 2021) were
323 retrieved for analysis, with 333251 sequences selected. Amino acid replacements, insertions,
324 and deletions with a frequency exceeding 0.1% were focused on our project. Amongst all S
325 protein mutations, D614G had the highest (94 %) mutation frequency. Mutations in B.1.1.7
326 (including 69-70del, Y144del, N501Y, A570D, T716I, S982A, D1118H and D614G) had a
327 mutation frequency of around 5%. In contrast, mutations in B.1.351 (D80A, D215G,
328 242-244del, R246I, K417N, E484K, N501Y, D614G, and A701V) had a much lower
329 mutation frequency (0.2%) (Fig.5A).

330 The change of binding activity between IgGs and mutant S1 was evaluated by ELISA.
331 The change of binding activity was defined by the value of $OD_{450_{\text{mutant S1}}} / OD_{450_{\text{S1}}}$. F61,
332 F163,C25, H184 and B110 showed low sensitivity against single-residue variants with
333 A475V and S477I. While, antibodies H121, C25, H184 and B110 exhibited a low sensitivity
334 towards N354K, A348T and A435S. Moreover, A199 exhibited a low sensitivity towards

335 R246A and P384L (Fig. 5B)

336 The neutralizing activity of mAbs against pseudovirus with mutant S protein was
337 evaluated via neutralization assay. The change of neutralizing activity was defined by the
338 value of $IC_{50_{SARS-CoV-2}} / IC_{50_{variant SARS-CoV-2}}$. The ratio less than 0.25 was deemed as
339 significantly. Remarkably, F61 and F163 efficiently neutralized multiple mutations within
340 RBD. F61 and F163 exhibited equivalent neutralization sensitivity against single-residue
341 variant A475V and S477I, which reduced the binding sensitivity of F61 and F163. Contrarily,
342 H121, C25, A8 were evaluated to have low potencies against Q414E. Similarly, the
343 neutralization sensitivity of C25, A8, H184, and B110 was reduced by L452R and
344 N354K(Fig.5C). Besides, F61 and H121 exhibited constant neutralizing activities against
345 mutations in B.1.1.7 and B.1.351 (K417N, E484K, N501Y) (Fig.5D). Furthermore, F61 and
346 H121 exhibited efficient neutralizing activity against B.1.1.7. F61 and H121 showed slightly
347 decreased neutralizing activity against B.1.351, which was still efficient. Synergistic of F61
348 and H121 exhibited similar neutralizing activities against the B.1.1.7, B.1.351 and WT virus
349 (Fig.5E)

350

351 **Discussion**

352 In this study, 12 SARS-CoV-2 specific IgGs were generated utilizing the Fab phage
353 antibody library technique which was more efficient than scFv phage library. Among the 12
354 selected antibodies, two of the RBD-specific antibodies (F61 and H121) had demonstrated
355 high neutralizing activity and high affinity against SARS-CoV-2. However, one RBD-specific
356 antibody failed to neutralize SARS-CoV-2. Meanwhile, our results from competitive ELISA
357 assay and computer docking revealed that F61 identified a linear epitope located in residues

358 G446-S494, which overlapped with ACE2 binding sites and H121 recognized a
359 conformational epitope located on the sideface of RBD which not overlap with ACE2 binding
360 sites. F61 and H121 maintained neutralizing activity against B.1.1.7 and showed a slightly
361 decreased but still efficient neutralization against B.1.351. Synergistic of F61 and H121
362 exhibited higher neutralizing activity against B.1.1.7 and B.1.351. Multiple mutations on
363 RBD could be efficiently neutralized by F61 and H121. Hence F61 and H121 had broad
364 neutralizing activity towards SARS-CoV-2 variants.

365 In this study, nine high affinity RBD-specific IgGs exhibited different neutralizing
366 activity. Two of them (F61 and H121) showed high neutralizing activity against
367 SARS-CoV-2. However, A199 failed to neutralize SARS-CoV-2, which suggested not all
368 RBD-specific antibodies were neutralizing antibodies. Meanwhile, our results from
369 competitive ELISA assay revealed that F61, F163 and B15 identified ACE2 competitive
370 epitopes. However, H121, C25, A8, H184 and B110 recognized epitopes which did not
371 overlap with ACE2 binding sites. A199 bound to a non-neutralization epitope that did not
372 overlap with remote from ACE2 binding sites. Results above suggested that neutralizing
373 capacities of antibodies did not rely on their ability to block RBD-ACE2 interaction. RBD
374 had three kinds of epitopes, thus, ACE2 competitive neutralization epitopes, ACE2
375 non-competitive neutralization epitopes, and non-neutralization epitopes.

376 Multiple mutations on S protein showed no resistant to F61 and H121.
377 Single-residue variants (K417N, Q493A, and N501Y) on essential residues within RBM for
378 ACE2 binding (Lan *et al.*, 2020; Wan *et al.*, 2020) and B.1.1.7 related mutations (N501Y,
379 P681H, T716I and S982A) could be efficiently neutralized by F61 and H121. Most of these

380 mutations positioned distant from target residues of F61 and H121. Therefore, the
381 neutralization sensitivity of F61 and H121 was barely altered by them. K417N increased the
382 neutralizing activity of F61 and H121. Replacement of the lysine with a shorter asparagine in
383 K417N(Laffeber *et al.*, 2021) increase the probability of conversion (Li *et al.*, 2021) to the
384 open conformation (Li *et al.*, 2021) and destroy the salt-bridge between K417 and residue
385 D30 on ACE2. The potential conversion in S protein trimer conformations might advance to
386 the neutralizing activity of the two antibodies.

387 F61 identified a linear epitope ranging from residues G446 to S494, which included
388 mutations E484K. K417N/T and E484K harbored by B.1.351 and P1 show resistance to
389 multiple neutralizing mAbs from the first and second class (Hoffmann *et al.*, 2021; Widera *et*
390 *al.*, 2021), including three mAbs with emergency use authorization(EUA):
391 REGN10933 (casirivimab), LY-CoV555 (bamlanivimab), and CB6
392 (etecevimab)(Kuzmina *et al.*, 2021; Tada *et al.*, 2021; Wang L. *et al.*, 2021a;
393 Wang P. *et al.*, 2021c). However, neither B.1.351 or mutations within the F61 identified
394 epitope (A475V、L452R、V483A、Q493A) were resistant to F61. Computer docking suggested
395 that F61 recognized a linear epitope on RBD, which was considered more stable than
396 conformational epitope. Therefore, the single-residue mutation within F61's epitope would
397 barely alter the neutralizing activity of F61. Moreover, P2C-1F11(Ge *et al.*, 2021) which
398 shares a similar epitope with F61 shows no reduction in neutralizing capacity against
399 B.1.351(Li *et al.*, 2021). Compared to CB6 (Shi *et al.*, 2020), another mAb that failed to
400 neutralize B.1.351 (Li *et al.*, 2021; Wang L. *et al.*, 2021a) in class one, F61 and P2C-1F11
401 identified a linear epitope and involved a relatively high number of residues in their binding

402 interface on RBD (Shi *et al.*, 2020; Ge *et al.*, 2021). Antibodies covering more critical
403 residues involved in the RBD-ACE2 interface might have a higher tolerance to viral
404 mutations. Moreover, viral mutations have a superposition effect on mAbs. Specifically, an
405 increasing number of mutation sites in the RBD is correlated with the immune escape from a
406 steadily increasing number of monoclonal antibodies (Li *et al.*, 2021; Widera *et al.*, 2021).
407 Therefore, with the accumulation of mutations in RBD protein, more and more antibodies,
408 including F61, would be escaped by SARS-CoV-2 variants.

409 H121 exhibited high levels of neutralization with epitopes on RBD remote from the
410 RBM and was believed non-overlap with ACE2 binding sites. H121 might lock the S trimer
411 in its closed state and hide the RBM region out of ACE2's accessibility (Benton *et al.*, 2020)
412 through binding to two neighboring RBDs within an S trimer, which was found in S309 and
413 S2M11(Pinto *et al.*, 2020; Tortorici *et al.*, 2020) sharing similarities with H121. Nevertheless,
414 mutation Q414E, instead of mutations within the H121 recognized epitopes (A348T, N354K,
415 N439K, A435S and A520S), escaped from H121. Q414E located remote from the epitope of
416 H121 on RBD. Q414E did not reduce the binding sensitivity of H121 to RBD (Fig. 5B),
417 determining other explanations for lower potency.

418 Revealed in our study, the cocktail of F61 and H121 exhibited increased neutralization to
419 SARS-CoV-2, and showed efficient neutralization to B.1.1.7, B.1.351 and WT SARS-CoV-2.
420 Therefore, the cocktail of F61 and H121 with broad neutralization improved treatment
421 efficacy by mitigating viral escape (Wang N. *et al.*, 2021b). F61 and H121 bond to distinct
422 and non-overlapping regions of the RBD and masked more epitopes on RBD (Piccoli *et al.*,
423 2020). Occupying more neutral epitopes prevented virus escape. Hence synergistic use of

424 antibodies with different epitopes should be investigated for developing future therapeutic
425 antibodies.

426 While designing antibody-based, efficient biological drugs, it is essential to precisely
427 delineate the interaction between antibody and antigen structures. To achieve this, we used
428 computer modeling and docking technique, which is more rapid and accurate compared to
429 X-ray crystallography and cryo-electron microscopy (cryo-EM), for the binding structure
430 prediction of antibodies and RBD. Since antibodies have a highly conserved framework,
431 homology models building for antibodies can be reasonably accurate (Yamashita *et al.*, 2014;
432 Leem *et al.*, 2016). Thus the models for F61 and H121 were highly reliable given that they
433 shared a similarity of more than 90% with the templates we used for homology modeling. The
434 ZDOCK method used in this study, a rigid-body docking algorithm based on fast Fourier
435 transforms (FFTs) (Pierce *et al.*, 2014), does not consider possible conformational changes,
436 causing possible deviation in docking results. Therefore, we will consider semi-flexible
437 docking protocols accounting for protein flexibility, such as HADDOCK (van Zundert *et al.*,
438 2016), and dynamic simulation methods for further model optimizations.

439 Succinctly, two antibodies (F61 and H121) obtained within our study were demonstrated
440 with high affinity and high-neutralizing activity against distinct RBD epitopes. Meanwhile,
441 evidence generated during our screening indicated that not all RBD-specific antibodies were
442 capable of performing neutralization. In comparison, antibodies could neutralize
443 SARS-CoV-2 without necessarily blocking the binding of RBD to ACE-2. Neutralizing
444 activity of F61 and H121 was mostly maintained when tested against multiple mutations and
445 variant B.1.1.7 and B.1.351, which revealed a broad neutralizing activity against

446 SARS-CoV-2 variants. While our findings could be further solidified with dynamic
447 simulation methods, they provided a guideline for the current and future vaccine design,
448 therapeutic antibody development, and antigen diagnosis of SARS-CoV-2 and its novel
449 variants.

450

451 **Acknowledgements**

452 We thank XL. Shi from Tsinghua University for her technical help in human Antibodies
453 expressing; TY. Chen and his research from INNOVITA for supporting antibody detection
454 reagents of SARS-CoV-2; HW.Wei from Jiangsu East-Mab Biomedical Technology for his
455 advice in high-yield antibody expressing; W.An for his technical help in performing SPR.

456 This work was supported by the National Science and Technology Major Project
457 (2018ZX10711-001)(2016ZX10004222-002).

458

459 **Author Contributions**

460 YY. Qu performed the experiments and wrote the paper; LA. Sun, MY. Wang, and performed
461 the experiments; YZ. Jing, FX. Zhan and YC. Wang contributed reagents/materials/analysis
462 tools. W. Wei, QL. Yin, MF. Liang, Y. Lang, JD. Li, C. Li and DX. Li analyzed and
463 discussed the data. MF.Liang, SW.Wang and WX.Guan designed the project and edited the
464 manuscript. All authors read and approved the final manuscript.

465

466 **COMPLIANCE WITH ETHICS GUIDELINES**

467 **Conflict of Interest** The authors declare that they have no conflict of interest.

468 **Animal and Human Rights Statement** This article does not contain any studies with human
469 or animal subjects performed by any of the authors.

470 **References**

- 471 Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. 2020. The proximal origin of
472 SARS-CoV-2. *Nat Med*, 26: 450-452.
- 473 Barbas CF, Burton DR. 1996 Selection and evolution of high-affinity human anti-viral antibodies
474 *Trends Biotechnol*, 14: 230-234.
- 475 Barbas CF, Kang AS, Lerner RA, Benkovic SJ. 1991. Assembly of combinatorial antibody libraries on
476 phage surfaces: the gene III site. *Proc Natl Acad Sci U S A*, 88: 7978-7982.
- 477 Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG,
478 Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP, Bjorkman PJ. 2020a.
479 Structural classification of neutralizing antibodies against the SARS-CoV-2 spike
480 receptor-binding domain suggests vaccine and therapeutic strategies. *bioRxiv*.
- 481 Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG,
482 Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP, Jr., Bjorkman PJ.
483 2020b. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature*,
484 588: 682-687.
- 485 Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. 2020.
486 Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion.
487 *Nature*, 588: 327-330.
- 488 Chi X, Renhong Y, Zhang J, Zhang GY, Zhang YY, Hao M, Zhang Z, Fan PF, Dong YZ, Yang YL,
489 Chen Z, Guo YY, Zhang JL, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J,
490 Zhou Q, Chen W. 2020. A neutralizing human antibody binds to the N-terminal domain of the
491 Spike protein of SARS-CoV-2. *Science*.
- 492 Daniel W, Wang NS, C. KS, G. JA, Hsieh CL, Olubukola A, G. BS, M. JS. 2020. Cryo-EM structure of
493 the 2019-nCoV spike in the prefusion conformation. *Science*: 1260–1263.
- 494 Ge J, Wang R, Ju B, Zhang Q, Sun J, Chen P, Zhang S, Tian Y, Shan S, Cheng L, Zhou B, Song S, Zhao
495 J, Wang H, Shi X, Ding Q, Liu L, Zhao J, Zhang Z, Wang X, Zhang L. 2021. Antibody
496 neutralization of SARS-CoV-2 through ACE2 receptor mimicry. *Nat Commun*, 12: 250.
- 497 Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A, Krüger N, Graichen L,
498 Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck H-M, Jahrsdörfer B,
499 Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S. 2021. SARS-CoV-2 variants
500 B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by
501 infection and vaccination. *bioRxiv*: 2021.2002.2011.430787.
- 502 Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J,
503 Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 2020.
504 Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*, 584: 115-119.
- 505 Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M,
506 Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA. 2008. Combinatorial antibody
507 libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus
508 neutralization strategies. *Proc Natl Acad Sci U S A*, 105: 5986-5991.

- 509 Kaushik S, Sowdhamini R. 2011. Structural analysis of prolyl oligopeptidases using molecular docking
510 and dynamics: insights into conformational changes and ligand binding. *PLoS One*, 6.
- 511 Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm L, Raviv Y, Shemer-Avni Y, Rosenberg E,
512 Taube R. 2021. SARS CoV-2 escape variants exhibit differential infectivity and neutralization
513 sensitivity to convalescent or post-vaccination sera. medRxiv.
- 514 Laffeber C, de Koning K, Kanaar R, Lebbink JHG. 2021. Experimental evidence for enhanced receptor
515 binding by rapidly spreading SARS-CoV-2 variants. bioRxiv.
- 516 Leem J, Dunbar J, Georges G, Shi J, Deane CM. 2016. ABodyBuilder: Automated antibody structure
517 prediction with data-driven accuracy estimation. *MAbs*, 8: 1259-1268.
- 518 Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L,
519 Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W,
520 Huang W, Wang Y. 2021. No higher infectivity but immune escape of SARS-CoV-2 501Y.V2
521 variants. *Cell*.
- 522 Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu Q, Li
523 X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y. 2020. The Impact of Mutations in
524 SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell*, 182: 1284-1294 e1289.
- 525 Liu L, Wang P, Nair MS. 2020. Potent neutralizing antibodies against multiple epitopes on
526 SARS-CoV-2 spike. 584: 450-456.
- 527 Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P, Pruitt L,
528 Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM. 2021. Sequence
529 Analysis of 20,453 SARS-CoV-2 Genomes from the Houston Metropolitan Area Identifies the
530 Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern.
531 medRxiv.
- 532 Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J,
533 Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and validation of a pseudovirus
534 neutralization assay for SARS-CoV-2. *Emerg Microbes Infect*, 9: 680-686.
- 535 Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto
536 D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino B, Minola A, Zatta F, Sprugasci N,
537 Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF, Gupta SV, Jin F,
538 Piumatti G, Lo Presti G, Pellanda AF, Biggiogero M, Tarkowski M, Pizzuto MS, Cameroni E,
539 Havenar-Daughton C, Smithey M, Hong D, Lepori V, Albanese E, Ceschi A, Bernasconi E,
540 Elzi L, Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink K, Virgin HW, Lanzavecchia A,
541 Corti D, Veessler D. 2020. Mapping Neutralizing and Immunodominant Sites on the
542 SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution
543 Serology. *Cell*, 183: 1024-1042 e1021.
- 544 Pierce BG, Wiehe K, Hwang H, Kim BH, Vreven T, Weng Z. 2014. ZDOCK server: interactive
545 docking prediction of protein-protein complexes and symmetric multimers. *Bioinformatics*, 30:
546 1771-1773.
- 547 Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De
548 Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE,
549 Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K,
550 Veessler D, Corti D. 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal
551 SARS-CoV antibody. *Nature*, 583: 290-295.
- 552 Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y,


- 553 Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS, Wang Q, Gao
554 GF, Yuan Z, Yan J. 2020. A human neutralizing antibody targets the receptor-binding site of
555 SARS-CoV-2. *Nature*, 584: 120-124.
- 556 Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, Navarro MJ, Bowen JE,
557 Tortorici MA, Walls AC, King NP, Veelsler D, Bloom JD. 2020. Deep Mutational Scanning of
558 SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.
559 *Cell*, 182: 1295-1310 e1220.
- 560 Tada T, Dcosta BM, Zhou H, Vaill A, Kazmierski W, Landau NR. 2021. Decreased neutralization of
561 SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
562 bioRxiv.
- 563 Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C,
564 Piccoli L, Pascall DJ, Dillen J, Lytras S, Czudnochowski N, Shah R, Meury M, Jesudason N,
565 De Marco A, Li K, Bassi J, O'Toole A, Pinto D, Colquhoun RM, Culap K, Jackson B, Zatta F,
566 Rambaut A, Jaconi S, Sreenu VB, Nix J, Zhang I, Jarrett RF, Glass WG, Beltramello M,
567 Nomikou K, Pizzuto M, Tong L, Cameroni E, Croll TI, Johnson N, Di Iulio J, Wickenhagen A,
568 Ceschi A, Harbison AM, Mair D, Ferrari P, Smollett K, Sallusto F, Carmichael S, Garzoni C,
569 Nichols J, Galli M, Hughes J, Riva A, Ho A, Schiuma M, Semple MG, Openshaw PJM, Fadda
570 E, Baillie JK, Chodera JD, Rihn SJ, Lycett SJ, Virgin HW, Telenti A, Corti D, Robertson DL,
571 Snell G. 2021. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading
572 antibody-mediated immunity. *Cell*, 184: 1171-1187.e1120.
- 573 Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. 2021. Mutation N501Y in RBD of
574 Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2.
575 bioRxiv.
- 576 Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen J,
577 Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker H, Zhou J,
578 Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE, Kaiser H,
579 Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C, Sprugasci N,
580 Culap K, Benigni F, Abdelnabi R, Foo SC, Schmid MA, Cameroni E, Riva A, Gabrieli A,
581 Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, G. S, Corti D, Fink K, Veelsler D.
582 2020. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple
583 mechanisms. *Science*, 370: 950-957.
- 584 van Zundert GCP, Rodrigues J, Trellet M, Schmitz C, Kastiris PL, Karaca E, Melquiond ASJ, van Dijk
585 M, de Vries SJ, Bonvin A. 2016. The HADDOCK2.2 Web Server: User-Friendly Integrative
586 Modeling of Biomolecular Complexes. *J Mol Biol*, 428: 720-725.
- 587 Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloninyi OK, Ransier A, Darko S,
588 Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Cale EM, Chang
589 LA, Corbett KS, DiPiazza AT, Gordon IJ, Leung K, Liu T, Mason RD, Nazzari A, Novik L,
590 Olia AS, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner D, Widge AT, Zhang B,
591 Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Baric RS, Graham BS,
592 McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. 2021a.
593 Antibodies with potent and broad neutralizing activity against antigenically diverse and highly
594 transmissible SARS-CoV-2 variants. bioRxiv.
- 595 Wang N, Sun Y, Feng R, ., Wang Y, Guo Y, Zhang L, Deng YQ, Wang L, Cui Z, Cao L, Zhang YJ, Li W,
596 Zhu FC, Qin CF, Wang X. 2021b. Structure-based development of human antibody cocktails

- 597 against SARS-CoV-2. *Cell*, 31: 101-103.
- 598 Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR,
599 Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Nair MS, Huang Y,
600 Ho DD. 2021c. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to
601 Antibody Neutralization. *bioRxiv*.
- 602 Wec A, Wrapp D, Herbert A, Maurer D, Haslwanter D, Sakharkar M, Jangra R, Dieterle M, Lilov A,
603 Huang D, Tse L, Johnson N, Hsieh C, Wang N, Nett J, Champney E, Burnina I, Brown M, Lin
604 S, Sinclair M, Johnson C, Pudi S, Bortz Rr, Wirchnianski A, Laudermitch E, Florez C, Fels J,
605 O'Brien C, Graham B, Nemazee D, Burton D, Baric R, Voss J, Chandran K, Dye J, McLellan J,
606 Walker L. 2020. Broad neutralization of SARS-related viruses by human monoclonal
607 antibodies. *369*: 731-736.
- 608 Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, Rabenau HF, Corman V, Drosten C,
609 Vehreschild MJGT, Goetsch U, Gottschalk R, Ciesek S. 2021. Bamlanivimab does not
610 neutralize two SARS-CoV-2 variants carrying E484K in vitro. *bioRxiv*.
- 611 Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, Xiao H, Fan Z, Tan S,
612 Wu G, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao G, Gao F, Liu L. 2020. A
613 noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its
614 receptor ACE2 *Science*, 368: 1274-1278.
- 615 Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y.
616 2020. Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2.
617 *bioRxiv*.
- 618 Yamashita K, Ikeda K, Amada K, Liang S, Tsuchiya Y, Nakamura H, Shirai H, Standley DM. 2014.
619 Kotai Antibody Builder: automated high-resolution structural modeling of antibodies.
620 *Bioinformatics*, 30: 3279-3280.
- 621 Yao W, Wang Y, Ma D, Tang X, Wang H, Li C, Lin H, Li Y, Zhong G. 2021. Spike mutations decrease
622 SARS-CoV-2 sensitivity to neutralizing antibodies but not ACE2-Ig in vitro. *bioRxiv*.
- 623 Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW,
624 Burton DR, Reincke SM, Pruss H, Kreye J, Nemazee D, Ward AB, Wilson IA. 2021.
625 Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
626 *bioRxiv*.
- 627 Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. 2020. The D614G
628 mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.
629 *bioRxiv*.

630

631

632 **Figures**



633

634 **Figure 1.** Generation and screening of antibodies from SARS-CoV-2 convalescent patients.

635 (A) Antibodies titer in the plasma of SARS-CoV-2 convalescent patients to SARS-CoV-2 N

636 protein and different fragments of SARS-CoV-2 S protein (RBD, S1, and S2). Experiments


637 were performed in duplicate and the error bars denote \pm SD, $n = 2$. (B) Heat-maps of Fab

638 clones against RBD ($n = 288$), S1 protein ($n = 288$) and S2 protein ($n = 288$). Each lattice

639 represented a Fab clone. (C) Binding specificity of the 12 candidate IgGs. The binding to

640 different spike proteins (RBD, S1, S2, S protein trimer, and virion) was determined by ELISA

641 Experiments were performed in duplicate, and the error bars denote \pm SD, $n = 2$.



642

643 **Figure 2.** Characterizing the binding profile of candidate IgGs. (A) The specificity of

644 SARS-CoV-2 specific IgGs detected by FACS. HEK 293T cells expressing SARS-CoV-2 S

645 protein were incubated with candidate mAbs or isotype IgG (HBV mAb) and then stained

646 with anti-human IgG FITC-conjugated antibody. Fluorescence intensity(FITC) negative cells

647 was less than 10^3 , and that of positive cells was around 10^4 . (B) The affinity of candidate

648 IgGs.. The affinity between antibodies (F61, F163, B15, H121, C25, A8, H184, B110 and

649 A199) and S1 were measured by BIAcore 8000 system. Non-competitive ELISA measured


650 the affinity between mAbs(H278, B120 and H285) and S2. (C) Neutralizing activity of

651 candidate IgGs against WT-SARS-CoV-2 pseudovirus and WT-authentic SARS-CoV-2.

652 Experiments were performed in duplicate, and the error bars denote \pm SD, n = 2. The

653 dashed line indicated a 50% reduction in viral infection.

654



655

656 **Figure 3.** Analysis of antibodies epitopes by Competition ELISA assays and FACS. (A)

657 Antigenic epitopes of nine RBD-specific IgGs were analyzed by competitive ELISA. Each

658 lattice shows a competitive percentage. Values less than 0.20 indicated that the antibody has

659 non-competitive epitopes, the value between 0.20 and 0.60 indicated intermediate binding

660 sites, and values greater than 0.60 indicated that the antibody shares overlapping or tight

661 epitopes. (B) ACE2 binding block assay by FACS. The mouse-Fc tag Fusion protein of

662 SARS-CoV-2 RBD (RBD-mFc) was pre-incubated with nine RBD-specific IgGs or isotype




663 IgG (HBV mAb) and then stained with HEK 293T cells expressing ACE2. Anti-human (Fc)

664 FITC-conjugated antibody and Anti-mouse (Fc) Texas red-conjugated antibody were used as

665 the secondary antibody. The X-axis represented the fluorescence intensity of human

666 antibodies labeled by FITC, and the Y-axis represented the fluorescence intensity of





667 RBD-mFc labeled by Taxes red.



669 **Figure 4.** Computer docking (ZDOCK) structure between F61/H121 and SARS-CoV-2 RBD.


670 (A) ZDOCK structure of the RBD and antibodies complex was shown on the left. RBD was in
671 red. F61 colored blue and pink. H121 was in orange and green. The complex of two
672 antibodies and RBD were superimposed to demonstrate their relative positions and
673 orientations. The footprint of F61 and H121 on RBD was shown in the middle. Blue and
674 orange represent the footprint of F61 and H121, respectively. Binding residues were listed on
675 the right. (B) The predicted Hydrogen-bond (H-bond) of F61 and H121. Green dashed lines
676 indicated H-bond. The H-bond of F61 was shown on the upper panel. The H-bond of H121
677 was shown on the lower panel. (C) Epitopes were overlapping between the two antibodies and
678 ACE2. The interaction between ACE2 and RBD was shown on the left. RBD was in red.
679 ACE2 colored bright green. The interactions between ACE2, RBD and two antibodies were
680 shown on the middle (F61) and left (H121). Color settings were consistent with those
681 mentioned above. Overlapping residues between each of the antibodies and ACE2 were listed
682 at the bottom.

683



685 **Figure 5.** Neutralization mutations of SARS-CoV-2 S protein and their effect on antibody
686 neutralizing activity. (A) Amino acid mutations on S protein. Mutations in B.1.1.7 lineage
687 were labeled red. Mutations in B.1.351 lineage were labeled blue. (B) The binding activity of
688 RBD-specific IgGs between mutant S1 protein and wild-type (WT) S1 protein was detected
689 by ELISA. The change of binding activity was defined by the ratio of OD450mutant S1 /
690 OD450WT S1. The dashed line indicated that the ratio was less than 0.5 or more than 1.5.
691 The significant changes were marked red for decreased. (C) Neutralization activities of nine
692 RBD-specific IgGs towards mutations on S protein were measured by pseudovirus. The
693 changes in neutralization activity was showed in the ratio of IC50 between the variant and
694 SARS-CoV-2 (GenBank: MN908947). The changes were marked with colored symbols, red
695 for decreased, blue for increased. (D) Neutralization activities of F61 and H121 towards
696 mutations K417N, E484K, and N501Y on S protein were measured by pseudovirus. The
697 changes in neutralization activity was showed in the ratio of IC50 between the variant and the
698 SARS-CoV-2 (GenBank: MN908947). The changes were marked with colored symbols, red
699 for decreased, blue for increased. (E) Neutralization activities of F61 and C121 towards B1.1.7
700 and B1.351 were measured by pseudovirus and authentic SARS-CoV-2. The y-axis represents
701 the value of IC50. The dashed line indicated that the fold change of IC50 was less than 0.25
702 (decrease) (marked red) or more than 4 (increase).
703

Fig S1



704

705 **Figure S1.** Characterization of candidates IgGs.(A) The specificity of candidates antibodies

706 detected by FACS. HEK 293T cells expressing SARS-CoV-2 S protein were incubated with

707 candidate antibodies or isotype IgG (HBV mAb) and then stained with anti-human IgG

708 FITC-conjugated antibody. The X-axis represented the fluorescence intensity of human

709 antibodies labeled by FITC. (B) The affinity between antibodies and S1 was measured by

710 BIAcore 8000 system.

711

712